Catalyst Pharmaceuticals/$CPRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
Ticker
$CPRX
Sector
Primary listing
Employees
181
Headquarters
Website
CPRX Metrics
BasicAdvanced
$2.6B
12.90
$1.65
0.70
-
Price and volume
Market cap
$2.6B
Beta
0.7
52-week high
$26.58
52-week low
$19.05
Average daily volume
1.6M
Financial strength
Current ratio
6.714
Quick ratio
6.359
Long term debt to equity
0.3
Total debt to equity
0.349
Profitability
EBITDA (TTM)
281.246
Gross margin (TTM)
83.03%
Net profit margin (TTM)
37.36%
Operating margin (TTM)
43.58%
Effective tax rate (TTM)
23.27%
Revenue per employee (TTM)
$3,090,000
Management effectiveness
Return on assets (TTM)
18.13%
Return on equity (TTM)
28.49%
Valuation
Price to earnings (TTM)
12.897
Price to revenue (TTM)
4.592
Price to book
3.04
Price to tangible book (TTM)
3.62
Price to free cash flow (TTM)
9.335
Free cash flow yield (TTM)
10.71%
Free cash flow per share (TTM)
2.278
Growth
Revenue change (TTM)
28.55%
Earnings per share change (TTM)
183.96%
3-year revenue growth (CAGR)
48.52%
3-year earnings per share growth (CAGR)
47.81%
10-year earnings per share growth (CAGR)
20.71%
What the Analysts think about CPRX
Analyst ratings (Buy, Hold, Sell) for Catalyst Pharmaceuticals stock.
Bulls say / Bears say
Catalyst posted record Q1 2025 total net product revenue of $141.4 million, up 43.6% year-over-year, driven by strong FIRDAPSE and AGAMREE demand (Press Release).
In Q2 2025, total net product revenue was $146.6 million, a 19.4% year-over-year increase, marking another quarter of broad-based portfolio growth (Press Release).
As of June 30, 2025, Catalyst had $652.8 million in cash and cash equivalents and no funded debt, supporting its financial flexibility for commercial expansion and potential M&A opportunities (Press Release).
FYCOMPA net product revenue fell 6.0% year-over-year to $34.3 million in Q2 2025, reflecting the effect of generic tablet competition on sales stability (Press Release).
Exclusivity protection for FYCOMPA oral suspension ends on December 15, 2025, exposing the product to possible generic competition and more pressure on future revenues (Press Release).
FIRDAPSE net product revenue growth slowed to 9.7% year-over-year in Q2 2025 from 25.3% year-over-year in Q1 2025, indicating possible market saturation in its main LEMS indication (Press Release; Press Release).
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.
CPRX Financial Performance
Revenues and expenses
CPRX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Catalyst Pharmaceuticals stock?
Catalyst Pharmaceuticals (CPRX) has a market cap of $2.6B as of October 16, 2025.
What is the P/E ratio for Catalyst Pharmaceuticals stock?
The price to earnings (P/E) ratio for Catalyst Pharmaceuticals (CPRX) stock is 12.9 as of October 16, 2025.
Does Catalyst Pharmaceuticals stock pay dividends?
No, Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders as of October 16, 2025.
When is the next Catalyst Pharmaceuticals dividend payment date?
Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals (CPRX) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.